HCPCS Code J1335: Injection, Ertapenem Sodium, 500 mg

Key Takeaways

HCPCS Code J1335 describes Injection, ertapenem sodium, 500 mg, a carbapenem antibiotic billed per 500 mg unit administered.

Medicare Part B reimburses J1335 at ASP + 6% under the physician fee schedule; rates update each quarter via CMS ASP files.

Coverage is carrier judgment, meaning individual Medicare Administrative Contractors determine coverage on a case-by-case basis.

Pabau’s claims management software helps infusion and IV therapy clinics track J-code billing, unit counts, and documentation requirements in one place.

HCPCS Code J1335: Definition and Clinical Description

Most ertapenem claims that get denied share a common root cause: unit miscounts and missing medical necessity documentation. HCPCS Code J1335 describes the injection of ertapenem sodium at 500 mg per unit, a classification that has been active in the CMS HCPCS Level II code set since January 1, 2004. Getting the unit calculation right is where billing accuracy begins.

Ertapenem (brand name Invanz, manufactured by Merck) is a carbapenem-class antibiotic indicated for serious bacterial infections including complicated intra-abdominal infections, community-acquired pneumonia, complicated urinary tract infections, and acute pelvic infections. The FDA-approved standard adult dose is 1 gram administered intravenously or intramuscularly once daily, which means most claims for HCPCS Code J1335 will report 2 units (2 x 500 mg). Providers who report 1 unit for a 1g dose are systematically underbilling; those who estimate rather than calculate are a compliance risk. According to CMS HCPCS guidance, the billing unit for J-codes must reflect the actual milligrams administered divided by the code’s dose increment.

Code Properties at a Glance

One verified factual error circulates in third-party coding resources: at least one site incorrectly describes J1335 as relating to ergotamine tartrate (a migraine treatment). That is a confirmed data error. HCPCS Code J1335 is exclusively for ertapenem sodium. Similarly, an older California Medi-Cal injection code list mapped J1335 to erythromycin lactobionate, which reflects a state-level crosswalk discrepancy. The federal HCPCS definition controls for Medicare and most commercial payers.

Medicare Reimbursement and Fee Schedule for J1335

Ertapenem is a relatively expensive antibiotic. Medicare Part B reimburses most physician-administered drugs, including those billed under HCPCS Code J1335, at the Average Sales Price (ASP) plus 6%. This formula applies in both physician office and hospital outpatient settings, though the payment mechanism differs between them.

Physician office (Physician Fee Schedule): The practice purchases ertapenem (buy-and-bill) and bills HCPCS Code J1335 on a CMS-1500 claim. Reimbursement is calculated at ASP + 6% per unit, where ASP is the weighted average net selling price reported by manufacturers to CMS each quarter. Practices should download the current CMS ASP drug pricing file before submitting claims, because rates change every quarter.

Hospital outpatient (OPPS): Under the Outpatient Prospective Payment System, J1335 may be packaged into the Ambulatory Payment Classification (APC) for the associated visit or procedure rather than reimbursed separately. Hospitals billing ertapenem under OPPS should verify the current packaging status in the annual OPPS rule issued by CMS Physician Fee Schedule lookup.

• ASP + 6%: Standard Part B formula for separately payable drugs in physician office settings
• WAC-based fallback: When ASP data is not available, CMS may apply a Wholesale Acquisition Cost (WAC) + 3% calculation
• OPPS packaging: Hospital outpatient claims may not receive a separate line-item payment; verify APC status before assuming reimbursement
• Quarterly updates: ASP pricing files are released by CMS in January, April, July, and October

Because coverage for HCPCS Code J1335 is classified as carrier judgment, individual Medicare Administrative Contractors (MACs) decide whether a claim qualifies. Some MACs publish Local Coverage Determinations (LCDs) for infusion drugs. Practices should check the applicable MAC’s policy before assuming automatic reimbursement. Claims management software that tracks payer-specific rules helps reduce surprises at the remittance stage.

How to Bill HCPCS Code J1335: Step-by-Step Workflow

Accurate billing for HCPCS Code J1335 follows a predictable workflow, but several steps are where practices commonly make errors. A claim for ertapenem involves more than placing the J-code on a CMS-1500 form.

1. Confirm the dose administered. Pull the actual administration record. For a standard 1g dose, report 2 units of J1335 (2 x 500 mg). For a renally adjusted dose (e.g., 500 mg in patients with CrCl 30 mL/min or less), report 1 unit. Units must reflect what was actually given, not a standard dose assumption.
2. Pair with the appropriate administration code. J1335 covers the drug only. The infusion administration itself requires a separate CPT code (typically 96365 for the initial hour of intravenous infusion, plus 96366 for each additional hour). Both the drug code and the administration code appear on the same claim.
3. Attach the correct diagnosis codes. Medicare requires medical necessity support from ICD-10-CM diagnosis codes that justify ertapenem therapy. See the diagnosis code pairing section below.
4. Apply modifiers when required. Modifier JA (intravenous administration) or JB (subcutaneous administration) may be required by some payers to indicate the route of administration. Check MAC and commercial payer policies. Modifier 59 may be needed to distinguish the drug administration from other services billed on the same date.
5. Include NDC information if the payer requires it. Medicaid and some commercial payers require the National Drug Code (NDC) reported alongside the J-code on the claim line. Format: 5-4-2 qualifier with the NDC number and the unit qualifier.
6. Submit on CMS-1500 or electronic equivalent (837P). Ensure the date of service, place of service code, and rendering provider NPI match what is in the medical record.

Practices running high-volume infusion services benefit from IV therapy EMR software that captures drug lot numbers, administered doses, and administration times at the point of care, generating claim-ready data rather than relying on manual transcription. Transcription errors between the administration record and the claim are one of the most common causes of J-code denials.

Streamline Your Infusion Drug Billing

Pabau helps IV therapy and infusion clinics capture drug administration data accurately at the point of care, reducing J-code billing errors and supporting clean claim submission.

Book a demo

Documentation Requirements for Ertapenem Claims

A clean claim is only as strong as the documentation supporting it. For HCPCS Code J1335, payers expect the medical record to establish three things: the indication for ertapenem, the actual dose and route administered, and the clinical response or treatment plan.

• Physician order: A dated, signed order specifying ertapenem, dose, route, frequency, and duration. An undated or unsigned order is sufficient grounds for denial.
• Diagnosis documentation: The clinical note must name the infection being treated and tie it to a specific ICD-10-CM code. “Infection” alone is not sufficient; the note should specify the site, organism where known, and severity indicators that justify IV or IM carbapenem therapy.
• Administration record: The actual time drug administration started and stopped, the IV site or IM injection site, the nurse or clinician administering, and any adverse reactions. This record supports the administration CPT code and the J-code unit count.
• Medical necessity rationale: For resistant organisms or prior therapy failures, include culture and sensitivity results or documentation of prior antibiotic failure. MACs reviewing carrier judgment claims look for clinical justification that a less expensive agent was not appropriate.

Outpatient infusion centers should also document the setting clearly. Services provided in a physician office (place of service 11) are reimbursed differently from those in an outpatient hospital (place of service 22). Placing the wrong code on the claim can result in payment at the wrong rate or an automatic denial. Compliance management tools that flag missing documentation fields before a claim is submitted save significant rework at the appeals stage.

ICD-10 Diagnosis Codes Commonly Paired with J1335

Because coverage for HCPCS Code J1335 is carrier judgment, the ICD-10-CM diagnosis code on the claim carries significant weight. Payers use the diagnosis to assess whether ertapenem was clinically appropriate.

The following ICD-10-CM codes appear most frequently alongside J1335 claims in outpatient infusion and physician office settings:

For outpatient parenteral antibiotic therapy (OPAT) programs using HCPCS Code J1335, adding Z79.2 as a secondary code alongside the primary infection diagnosis helps establish that the ertapenem course is part of a planned therapy regimen, not an isolated acute episode. Practices providing IV therapy services in physician offices should verify with their MAC whether a Z-code secondary is expected on the claim.

Related J-Codes and HCPCS Crosswalk Considerations

Billing staff working with carbapenem antibiotics and broad-spectrum IV anti-infectives should be familiar with the J-codes that sit adjacent to J1335 in the HCPCS Level II table. Selecting the wrong J-code for a different drug is one of the most straightforward denial causes to prevent. You can verify current code status for any J-code using the CMS HCPCS overview or the AAPC Codify HCPCS lookup.

• J0285: Ampicillin sodium, per 500 mg (different beta-lactam antibiotic; never substitute for J1335)
• J0290: Ampicillin sodium/sulbactam sodium, per 1.5 g (combination agent; different spectrum)
• J0696: Ceftriaxone sodium, per 250 mg (third-generation cephalosporin; commonly used in OPAT but a different drug class)
• J1335: Ertapenem sodium, 500 mg (this code)
• J0287 / J0288 / J0289: Amphotericin B formulations (antifungal; listed for reference only)

Practices that manage prescription management and drug ordering alongside billing will find that keeping the drug dispensed, the NDC, and the J-code linked in the clinical record reduces crosswalk errors significantly. When a drug changes from buy-and-bill to a pharmacy benefit, HCPCS Code J1335 may no longer be billed on a Part B claim; the prescription routes through Part D instead. The setting and benefit type must be confirmed before claim submission.

Common Denial Reasons and How to Prevent Them

Denials on HCPCS Code J1335 cluster around a predictable set of failure points. Knowing them in advance is the most efficient compliance investment a billing team can make.

• Incorrect unit count: Reporting 1 unit for a 1g dose is the most common billing error. The formula is: total mg administered divided by 500 = units to report. A 1g dose = 2 units.
• Missing modifier: Some MACs and commercial payers require modifier JA (IV administration) or JB (subcutaneous). Check payer-specific policies before submission.
• No NDC on claim: Medicaid and some commercial plans reject J-code claims without an accompanying NDC. Format it as the 11-digit NDC with qualifier N4 on the claim line.
• Carrier judgment denial: The MAC determined coverage was not established. Resolution requires an appeal with supporting clinical documentation, including culture results, prior treatment failures, or resistance documentation.
• Wrong place of service: A claim billed with POS 11 (physician office) for a service actually delivered in an outpatient hospital setting (POS 22) triggers automatic mismatch edits.
• Duplicate claim: OPAT patients receiving daily ertapenem may trigger duplicate claim edits if dates of service overlap. Ensure each date is billed as a separate claim line.

Practices using integrated claims management software can build pre-submission edit checks that flag unit mismatches, missing modifiers, and absent NDC fields before the claim leaves the practice. Catching these errors internally is substantially cheaper than working rejections through the payer’s appeals process. The AAPC Codify HCPCS lookup is also a reliable reference for verifying current modifier requirements per code.

Expert Picks

Need to understand the full landscape of HCPCS J-code billing? Billing Codes resource hub covers HCPCS and CPT articles for infusion, drug administration, and specialty clinic billing.

Running an IV therapy clinic and want tighter billing workflows? IV Therapy EMR Software from Pabau integrates administration records with claim-ready data capture.

Looking for a reference on managing drug administration compliance across your practice? Compliance Management Software helps practices track payer-specific requirements and documentation standards.

Conclusion

Billing errors on ertapenem claims are almost entirely preventable. The unit count is deterministic, the documentation requirements are consistent, and the modifier rules are published. What creates denials is the gap between what the clinical record captures and what the billing team sees when preparing the claim.

Pabau’s claims management software connects drug administration records to claim preparation, helping infusion and IV therapy practices submit accurate J1335 claims with the right unit counts, modifiers, and diagnosis codes in place. To see how it works for your clinic, book a demo and we’ll walk you through the workflow.

Frequently Asked Questions